Tools   Select Another Resource Report Type

http://dererumnatura.us/

His research interests cover many different questions in population genetics and molecular evolution. He considers himself an evolutionary geneticist, with strengths in computational biology and stochastic models. He has worked on frequency-dependent selection models, spatial genetic models, indel evolution models, sequence alignment, and phylogenetic models. His current research involves estimating indel rates and length distributions, applying population genetic models to phylogeny reconstruction, and finding de novo mutations and SNPs from next-gen sequencing of human genomes. In addition to running De Rerum Natura, Reed also manages the largest group blog on evolution, The Pandas Thumb. In addition he develops plugins and hacks for the Movable Type blogging software. He is an expert on dispatching MT under FastCGI and Lighttpd, as well as integrating it with jQuery. He was editor and designer of The Open Laboratory: The Best Science Writing on Blogs 2007. He is co-creator of Prof. Steve Steve. Partners. Movable Type Site Meter Melody Lulu

Proper citation: De Rerum Natura (RRID:SCR_008475) Copy   

•   Source: SciCrunch Registry

https://research.uga.edu/core-facilities/

University of Georgia Core Facilities provide equipment and services to researchers at UGA, other universities, government agencies, nonprofit organizations and industry. These facilities make use of highly specialized scientific equipment, diagnostic tools, adaptable prototyping processes and mechanical production shops.

Proper citation: University of Georgia Labs and Facilities (RRID:SCR_011033) Copy   

•   Source: SciCrunch Registry

http://informedmedicaldecisions.org/

Mission The Foundation for Informed Medical Decision Making is a non-profit organization dedicated to assuring that people understand their choices and have the information they need to make sound decisions affecting their health and well being. To accomplish our mission: We promote understanding and adoption of informed medical decision-making. We organize and frame medical evidence in an unbiased manner to help people evaluate their options, particularly in instances where differences in individual preferences and perspectives are likely to affect personal choice. We sponsor research to expand knowledge of how to improve decision quality in health care. Medical Evidence The science of medical care is advancing at a rate that makes the delivery of quality patient-focused care an enormous challenge. New information about disease biology and genetics, rapid development of new tests and treatments, and the shift in disease from largely acute to largely chronic are all important contributing factors. Patient Perspective Medical research on practice variation indicates that patient perspectives are often less important in treatment decisions than factors having little to do with patients or their illnesses, such as geography, economics or supplier-induced demands. The Foundation brings the patient perspective into focus by interviewing real patients who can talk about the choices they made and why. Without the perspective of the patient, we cannot achieve a quality medical decision. Informed Medical Decisions The Foundation believes that it is the convergence of the two concepts: medical evidence and patient perspectives that create a truly informed decision in medical care. Funding The Foundation has worked in a unique partnership with Health Dialog since 1997. Health Dialog delivers patient support services to employers and health plans that are committed to providing excellence to their members or employees. As of July 2006, Health Dialog served seventeen million people through its contracts with healthcare insurers and corporations. Access to the Foundation''s decision support materials is a key benefit that Health Dialog''s clients receive. Health Dialog produces the Foundation''s new programs and distributes decision support materials and services to patients. A portion of Health Dialog''s revenue goes to the Foundation in the form of royalties to support the development of new decision support materials and research on how best to support patient decisions. The Foundation does not accept funding from any source that has a financial interest in any particular approach to medical testing or treatment. Foundation employees and clinical content experts do not accept support from companies that commercially market any kind of treatment or device that might be relevant to a program.

Proper citation: Foundation for Informed Medical Decision Making (RRID:SCR_008509) Copy   

•   Source: SciCrunch Registry

http://www.kew.org/index.htm

Throughout its history, the Royal Botanic Gardens, Kew has made important contributions to increasing the understanding of the plant kingdom with many benefits for mankind. Today it is still first and foremost a scientific institution. With its collections of living and preserved plants, of plant products and botanical information, it forms an encyclopaedia of knowledge about the plant kingdom.

Proper citation: Royal Botanic Gardens Kew (RRID:SCR_010543) Copy   

•   Source: SciCrunch Registry

http://tikus.gsf.de

THIS RESOURCE IS NO LONGER IN SERVICE, documented on October 23, 2014. Consortium that generated a reference library of gene trap sequence tags (GTST) from insertional mutations generated in mouse embryonic stem (ES) cells. The gene trap database represents a repository of sequences produced in a large scale gene trap screen in mouse ES cells using various gene trapping vectors which are delivered either by electroporation or retroviral infections. A type of retroviral gene trap vector has been developed that can induce conditional mutations in most genes expressed in mouse embryonic stem (ES) cells. The vectors rely on directional site-specific recombination systems that can repair and re-induce gene trap mutations when activated in succession. After the gene traps are inserted into the mouse genome, genetic mutations can be produced at a particular time and place in somatic cells. In addition to their conditional features, the vectors create multipurpose alleles amenable to a wide range of post-insertional modifications. Here they have used these directional recombination vectors to assemble the largest library of ES cell lines with conditional mutations in single genes yet assembled, presently totaling 1,000 unique genes. The trapped ES cell lines, which can be ordered from the German Gene Trap Consortium, are freely available to the scientific community.

Proper citation: German Gene Trap Consortium (RRID:SCR_008532) Copy   

•   Source: SciCrunch Registry

https://www.unr.edu/ncar/infrastructure

Nevada Center for Applied Research coordinates access to Shared Research Facilities extensive resource of labs with cutting edge research and development equipment available to internal University community and external clients from industry, government, research organizations and other institutions.In addition to services and instrumentation, we offer support from highly experienced staff with expertise in designing and conducting experiments and analyzing data. Many facilities can also provide training and education upon request.

Proper citation: University of Nevada Reno Labs and Facilities (RRID:SCR_011008) Copy   

•   Source: SciCrunch Registry

http://www.emqn.org

Welcome to the EMQN website. EMQN is a not-for-profit organisation promoting quality in molecular genetic testing through the provision of external quality assessment (proficiency testing schemes) and the organisation of best practice meetings and publication of guidelines. The European Molecular Genetics Quality Network (EMQN) started in October 1998 after a successful pilot trial. From January 1999 to March 2002, the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515). From April 2002, the network is supported by subscriptions from it users. External Quality Assessment (EQA): There are 26 EQA schemes being offered in 2010. To participate you must be a registered member of the network. For more information on EQA schemes, click the link here. Best Practice: EMQN is actively promoting ''best practice'' meetings on individual diseases. To assist in this process, EMQN will be organising best practice meetings. To participate you must be a registered member of the network. Following the meeting, draft best practice guidelines are produced and publised on this and other related websites, for example, the web site of the UK Clinical Molecular Genetics Society (CMGS). To find out more about best practice click here. Administration: The EMQN is based at the National Genetics Reference Laboratory (Manchester), St Mary''s Hospital, Manchester, The United Kingdom. The Network is co-ordinated and administered by Dr''s Rob Elles and Simon Patton. A management group is responsible for the activities and direction of the network. National partners in different countries help to disseminate information about the network. Quality Policy The EMQN provides a comprehensive range of quality assurance programs for molecular genetics to laboratories and industry worldwide. The European Molecular Genetics Quality Network (EMQN) is committed to helping ensure diagnostic molecular genetic laboratory test results are accurate, reliable and comparable wherever they are produced. The EMQN will provide a high quality and timely service which takes into account the needs and requirements of its users. Objectives To help to raise and maintain the standards of diagnostic clinical molecular genetic testing. To undertake and promote educational activities. To be a leading authority in quality assurance . To design and provide the best possible materials and data management. To design and provide quality reports that are timely and valid. To provide professional support and consultation. To develop new programs as required. To participate in peer review. To strive for continual improvement of the quality system. Sponsor. the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515

Proper citation: European Molecular Quality Network (RRID:SCR_008494) Copy   

•   Source: SciCrunch Registry

http://narayanahospitals.com/cellsofhope/

Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center (NHTB-SCRC) is a joint venture between Rotary Bangalore Health City (RBHC) and Narayana Hrudayalaya. Our mission is to create awareness on Cord Blood Banking among the masses. Our vision is to make sure that every pregnant mother in India is able to afford to bank her child''s cord blood and cord tissue in a novel form of ������??Biological Insurance������??. The center would also assist in research and development of newer stem cell therapies. These goals are met while ensuring patient safety and well being by maintaining compliance with ICMR guidelines, Good Manufacturing Practice (GMP) guidelines, strict confidentiality and adherence to ethical standards. The private cord blood bank would store cord-blood and cord tissue derived stem cells for the exclusive use of clients who would pay for the cryo-storage, for a period of 21 years. These samples would be used for the child or its siblings anytime in the future, for therapy of various medical conditions. The public cord blood bank would enable us to collect cord blood from delivery and birthing centers, process these specimens, type their HLA signature and store them in ultra-low temperature conditions for use on prospective recipients. These recipients would have to be matched against their HLA signature with the stored stem cell concentrate. Patients with a disease treatable by stem cell therapy would have to have their HLA type known and they approach us for treatment. Such patients would be matched against our library of samples to identify a suitable match which would then be issued at a nominal cost. The cost of therapy would however be separate and informed to the patient before embarking on the treatment.

Proper citation: Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center (RRID:SCR_010680) Copy   

•   Source: SciCrunch Registry

http://www.zymogenetics.com.

Founded in 1981, ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins. ZymoGenetics is publicly traded (NASDAQ: ZGEN) and headquartered in Seattle, Washington in the historic Seattle City Light Steam Plant building. Our mission is to create novel protein drugs that will significantly help patients fight their diseases. We have contributed to the discovery or development of six recombinant protein products now marketed by other companies. Current programs target viral infection, cancer, inflammatory diseases and bleeding. Our first internally developed product, RECOTHROM Thrombin, topical (Recombinant), was approved by the U.S. Food and Drug Administration (FDA) on January 17, 2008 for use as a topical hemostat to control moderate bleeding during surgical procedures and is now marketed in the United States. We have a promising pipeline of novel therapeutics, which we are developing on our own or in collaboration with partners.

Proper citation: Zymo Genetics (RRID:SCR_008602) Copy   

•   Source: SciCrunch Registry

http://repeatmasker.genome.washington.edu

Welcome to the Department of Genome Sciences, which began in September 2001 by the fusion of the Departments of Genetics and Molecular Biotechnology. Our goal is to address leading edge questions in biology and medicine by developing and applying genetic, genomic and computational approaches that take advantage of genomic information now available for humans, model organisms and a host of other species. Our faculty study a broad range of topics, including the genetics of E. coli, yeast, C. elegans, Drosophila, and mouse; human and medical genetics; mathematical, statistical and computer methods for analyzing genomes, and theoretical and evolutionary genetics; and genome-wide studies by such approaches as sequencing, transcriptional and translational analysis, polymorphism detection and identification of protein interactions. Our chair, Dr. Robert Waterston, joined the department in January 2003. Our department includes both faculty with primary appointments in Genome Sciences, as well as adjuncts in other departments and Seattle institutions. Nine faculty are members of the National Academy of Sciences, including 2001 Nobel Prize winner Dr. Lee Hartwell, who conducted much of his groundbreaking work in the Department of Genetics. Five training faculty are Howard Hughes Medical Institute Investigators. Graduate research in the Department leads to a Ph.D. in Genome Sciences and students may also choose to participate in the Computational Molecular Biology or Molecular Medicine programs. Our department has around 55 - 60 graduate students at any given time and has moved into the new William H. Foege Building.

Proper citation: UW Genome Sciences (RRID:SCR_008562) Copy   

•   Source: SciCrunch Registry

http://www.ra-map.com/p/about-project.html

RA MAP is a public-private collaborative project into early Rheumatoid Arthritis (RA). Our goal is to: identify the key predictors of clinical response and remission in RA patients, and identify those individuals at high risk of developing RA. By understanding the human immune system in RA through the study of biological samples from RA patients we plan to develop an ''immunological toolkit'' measuring the immune status of healthy individuals and patients.

Proper citation: RA MAP (RRID:SCR_010492) Copy   

•   Source: SciCrunch Registry

http://ecvam.jrc.it/

ECVAM was created by a Communication from the Commission to the Council and the Parliament in October 1991*, pointing to a requirement in Directive 86/609/EEC** on the protection of animals used for experimental and other scientific purposes, which requires that the Commission and the Member States should actively support the development, validation and acceptance of methods which could reduce, refine or replace the use of laboratory animals: Article 7.2: An experiment shall not be performed if another scientifically satisfactory method of obtaining the result sought, not entailing the use of an animal, is reasonably and practicably available. Article 23: The Commission and Member States should encourage research into the development and validation of alternative techniques which could provide the same level of information as that obtained in experiments using animals, but which involve fewer animals or which entail less painful procedures, and shall take such other steps as they consider appropriate to encourage research in this field. ECVAM has been established in 1992 as a unit of the Environment Institute, part of the Joint Research Centre, and has been transferred to, at that time, newly formed Institute for Health and Consumer Protection in Ispra, Italy in 1998 of which ECVAM is still part of. Duties of ECVAM As defined in the Communication of the European Commission to Council and the European Parliament in October 1991*: 1. To coordinate the validation of alternative test methods at the European Union level. 2. To act as a focal point for the exchange of information on the development of alternative test methods. 3. To set up, maintain and manage a data base on alternative procedures. 4. To promote dialogue between legislators, industries, biomedical scientists, consumer organisations and animal welfare groups, with a view to the development, validation and international recognition of alternative test methods. Moreover, ECVAM should help to expand the JRC''s role in prenormative research. ECVAM thus seeks to promote the scientific and regulatory acceptance of alternative methods which are of importance to the biosciences, through research, new test development and validation, and the establishment of specialised databases, with the aim of contributing to the replacement, reduction and refinement of laboratory animal precedures (in accordance with the 3Rs concept of Russell & Burch***) Due to the political sensitivity of its duties, ECVAM, uniquely at the JRC, has its own Scientific Advisory Committee (ESAC) with participation from all Member States, relevant industrial associations, academic toxicology, the animal welfare movement, as well as other Commission services with interest in the alternatives topic area. The Validation Process Validation is the process by which the reliability and relevance of a procedure are established for a specific purpose. In 1995, based upon experience gained during several recent large-scale validation studies, and in consultation with various international experts (including members of ERGATT), ECVAM published recommendations concerning the practical and logistical aspects of validating alternative test methods (ECVAM workshop report 5). Five main stages in the evolution of new test methods were identified: test development; prevalidation; validation (involving a formal interlaboratory study with the testing of coded chemicals); independent assessment; and progression toward regulatory acceptance. ECVAM has implemented a prevalidation scheme, which includes three main phases: protocol refinement, protocol transfer, and protocol performance. The objective of the prevalidation process is to ensure that any method included in a formal validation study adequately fulfills the criteria defined for inclusion in such a study, so that financial and human resources are used more efficiently, and so that there is a greater likelihood that the expectations of those in the scientific, regulatory and animal welfare communities, who seek the replacement of current animal tests by relevant and reliable alternative methods, will be met. In 2004, ECVAM has published the Modular Approach to the ECVAM Principles on Test Validity (select from the top-menu bar the sector Publications followed by ECVAM Selected Articles) that makes the validation process more flexible, by breaking down the various steps in validation into indipendent modules, and defining for each module the information needed for assessing test validity. Collaborations ECVAMs activities are undertaken in collaboration with numerous laboratories and organisations in the EU Member States, and all over the world. ECVAM also works in close collaboration with other Commission services, such as DG Environment, DG Enterprise, DG Research and DG Health and Consumer Protection. Sponsor. This is a Five years project funded by DG RTD that aims to develop a testing strategy to improve the prediction of oral acute toxicity using non-animals based systems.

Proper citation: European Centre for the Validation of Alternative Methods (RRID:SCR_008504) Copy   

•   Source: SciCrunch Registry

http://eurobonet.pathobiology.eu/cd/

Integration objectives Training and education Standardisation in technology Share of material Web based sharing of information and communication Translational research Spreading excellence objectives Coordinated by Treviso Courses on bone pathology and molecular biology Standard Operation Protocols Web-based discussion forums Research objectives Work packages on: Cartilaginous Tumours (Leiden) Osteogenic Tumours (Munster) Giant Cell Tumours (Oxford) Ewing Sarcoma (Bologna)

Proper citation: Eurobonet (RRID:SCR_008503) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/CSCB/Default.aspx

Biospecimen repository that provides scientists with the opportunity to bank their pluripotent stem cell lines and develops in-house induced pluripotent stem cell (iPSC) lines for distribution. They have developed core capabilities to maintain, characterize, bank, and distribute important stem cell resources. The SCB performs extensive identification and characterization testing for all submitted human induced pluripotent stem cell (iPSC) and mouse embryonic stem cell (mES) lines. The identification and quality control measures include karyotype analysis, microsatellite analysis for parental cell line identity matching, sterility testing, and assessment of viability after cryopreservation. Pluripotency characterizations performed by SCB vary depending upon the distributing repository. * NIGMS iPSCs: Surface antigen expression, Embryoid body formation, Pluritest Gene Expression assay * NINDS iPSCs: Surface antigen expression, Embryoid body formation * NIA mES: Surface antigen expression, Embryoid body formation, Transgene induction Each characterized human iPSC line and mES line released for distribution is provided with a Certificate of Analysis, which includes information regarding characterization and quality of the line, images and links to original publications. The human iPSCs distributed by Coriell are strictly for research purposes and cannot be used in human subjects. All terms described in the Material Transfer Agreement (NIGMS and NINDS Repositories) or Assurance Form (NIA Repository) for the stem cell line must be agreed to prior to using stem cell lines from Coriell.

Proper citation: Coriell Institute Stem Cell Biobank (RRID:SCR_008745) Copy   

•   Source: SciCrunch Registry

http://ctn.uwaterloo.ca/index.html

The Centre for Theoretical Neuroscience (CTN) was recently established at the University of Waterloo. The Centre is a growing research initiative of the University. The Centre consists of several labs focused on various areas of theoretical neuroscience (aka computational neuroscience). At present, the Centre consists of faculty members from Applied Mathematics, Biology, Psychology, Engineering, Philosophy, Statistics, Computer Science, and their students. The Centre has established a unique Graduate Program in theoretical neuroscience and hosts a regular academic colloquium series. The Centre also hosts the annual public Waterloo Brain Day lectures. The Centre is currently expanding, running searches for additional core faculty. The distinguished faculty of the Centre include two Canada Research Chairs and a fellow of the Royal Society of Canada. In addition, the Centre has a number of student researchers, both graduate and undergraduate, and hosts postdocs and visiting researchers. The Centre also hosts a graduate program for students wishing to obtain an officially recognized specialization in theoretical neuroscience. Faculty at the Centre pursue work on purely theoretical questions regarding the foundational principles guiding the function of neural systems, as well as constructing detailed neurobiological models of specific brain areas.

Proper citation: Center for Theoretical Neuroscience; University of Waterloo (RRID:SCR_008747) Copy   

•   Source: SciCrunch Registry

http://www.cytopathology-foundation.org/

Cytopathology Foundation is a non-profit organization dedicated to the health care for the advancement of art and science of Cytopathology dealing with study of cells for proper disease management especially cancer. Cytopathology is a well established diagnostic sub-specialty of pathology. Instead of using surgically removed tissue to arrive at a diagnosis it attempts to identify diagnostic and prognostic information from dispersed cells obtained by non-invasive or minimally invasive techniques. An example, and its greatest success story thus far, is the role it has played in the battle with cervical cancer. The introduction of the Pap smear has contributed immensely to the early diagnosis and significantly decreased mortality of cervical cancer. Activities of the foundation 1. Support the mission statement in general. 2. Support the editorial and publication expenses of CytoJournal. 3. Future activities may include publication and marketing of cytopathology related literature, to generate funds. 4. Support any other scholarly activities in Cytopathology and related areas.

Proper citation: Cytopathology Foundation (RRID:SCR_008467) Copy   

•   Source: SciCrunch Registry

http://www.cienciasecognicao.org

Portal for scientific dissemination, teaching and interdisciplinary research that includes the integration of the sciences of mind, brain and education in Brazil. The contents are in Portuguese. English version coming soon.

Proper citation: Science and Cognition Organization (RRID:SCR_009436) Copy   

•   Source: SciCrunch Registry

http://www.biobancusa.com/

BioBancUSA is a leading biotechnology company specializing in white blood cell collection, processing, cryopreservation and storage service. BioBancUSA, a private company headquartered in Monterey, California, is the exclusive licensee of the original patent for the collection, processing and cryopreservation technology of white blood cells, giving you the assurance of both technical integrity and legal legitimacy that you can count on. BioBancUSA is dedicated to providing our clients with the highest quality immune cell preservation for their future medical use. We are committed to the most advanced technology, exceptional, personalized service and leading-edge innovation to benefit our customers, health care providers, shareholders and employees.

Proper citation: Biobanc USA (RRID:SCR_010622) Copy   

•   Source: SciCrunch Registry

http://tronolab.epfl.ch

Retroelements constitute important evolutionary forces for the genome of higher organisms, yet their uncontrolled spread, whether from endogenous loci or within the context of viral infections, can cause diseases such as cancer, hepatitis and AIDS. Correspondingly, a variety of host-encoded activities limit this process, belonging to a line of defense commonly called intrinsic or innate immunity, which notably contributes to taming endogenous retroelements and to restricting the cross-species transmission of retroviruses. Our work aims at characterizing the relationship between retroelements and their hosts, which has recently led us to become more generally interested in epigenetic mechanisms regulating the expression of mammalian genomes.

Proper citation: Tronolab (RRID:SCR_008580) Copy   

•   Source: SciCrunch Registry

http://www.rucdr.org/

RUCDR is a biobank and a service organization that maintains human blood, serum, saliva, tissue and the genetic products derived from those. Services include technical consultation and logistical support for biobanking. Researchers can order biomaterials and apply for phenotypic / genotypic data.

Proper citation: Rutgers Cell and DNA Repository (RRID:SCR_010624) Copy   

•   Source: SciCrunch Registry